Keywords: astrazeneca, crestor, hold, nrx, statins, market, 28-week
AstraZeneca's Crestor hold 6.1% of US NRx statins market
Article | 22 March 2004
US 28-week post-launch IMS Health data for AstraZeneca's cholesterol-lowering drug Crestor (rosuvastatin) show that prescriptions continue to increase, with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
